Abstract [248 words, max 250 words] Background: Recent studies linking radiation exposure from pediatric computed tomography
Introduction
Five epidemiologic studies on cancer following radiation exposure from pediatric Computed Tomography (CT) scans have shown elevated risks of leukemia and brain tumors (1-5) and others are underway (6,7). These studies are record-linkage cohort studies on large numbers of patients collected from existing databases (health insurances, hospitals) with limited or no information on potential confounding factors which may bias the radiation-cancer association.
A confounder is associated with the exposure in the source population from which the cases arise and with the disease under study in the non-exposed population, and is not on the causal pathway.
Concerns have been raised about a possible overestimation of radiation-related risks in studies of pediatric CT scans and cancer due to confounding by indication (also called reverse causation) (8-13). Confounding by indication occurs if the reason for a CT scan is associated with cancer risk.
With regard to CT studies, primary concern is about two sources of confounding by indication, namely sub-clinical tumors and cancer susceptibility syndromes (CSS). Cancer in a sub-clinical prodromal phase may cause symptoms which necessitate a CT scan. The CT radiation dose is solely associated with detection and not with disease causation. This source of confounding by indication is often amenable to evaluation through the use of an exclusion period. CSS, on the other side, are congenital disorders and are associated with increased cancer risk at one or more sites (14) . The potential for confounding arises because CSS patients may have CT scans for early symptoms of the syndrome, diagnostic purposes, monitoring of disease progression, or associated comorbidities (15, 16) . We focus on CSS because we believe they are the potentially most important source of confounding by indication.
In the absence of empirical data, it appears plausible that CSS patients are more likely to have one or multiple CT scans compared to children without CSS. Since CT scans do not cause CSS, the observed increased risk of cancer following pediatric radiation exposure from diagnostic imaging might be partly due to confounding by CSS. The largest studies published to date did not adjust their risk estimates for CSS. Such data are likely not available, since most countries do not have registries or other easily accessible resources to identify CSS patients. For CSS where the direction of the potential confounding is known but not its magnitude, we use plausible scenarios to assess the magnitude of possible bias in studies of radiation exposure from pediatric CT scans (17) .
This report focuses on pediatric CT scans, because children are more radiosensitive than adults. The endpoints of primary concern are leukemia and brain tumors. These diseases are the most common radiogenic malignancies among children, adolescents, and young adults and are the primary focus of published and ongoing epidemiologic studies on cancer risk following pediatric CT scan exposure (18) . Nevertheless, the results of our analyses provide guidance for all epidemiological studies of diagnostic imaging and cancer risk.
Materials and methods
In short, we identify CSS predisposing to leukemia or brain tumors and characterize: their prevalence in the general population, the strength of their association with leukemia and/or brain tumors, and their life expectancy. We then calculate the magnitude of CSS-related confounding of relative risk (RR) estimates for leukemia and brain tumors after diagnostic CT scans, under various assumptions for the association between CSS and the frequency of CT scans.
Identification and characterization of CSS
We identified CSS that are associated with increased risk of either leukemia, or brain tumors, or both, at any age based on two major sources of information: (1) a table of genetic syndromes predisposing to childhood cancer from a thorough systematic review of the literature by a pediatric oncologist who specializes in these syndromes (JM) (14) and (2) a systematic overview of familial cancer syndromes (15) . Thirdly, we consulted with physicians specializing in genetic syndromes at three university hospitals (see Acknowledgement) to identify any other rare eligible CSS. Then the pediatric oncologist (JM) assessed the likelihood of medical radiation exposures for screening or health care for each of the CSS.
Finally we queried the MEDLINE database for each CSS to determine prevalence, risk of leukemia and brain tumors, life expectancy, and the likelihood of diagnostic imaging (in particular CT scans). We included articles regardless of study design, as well as book chapters and systematic reviews. Articles were identified by name of the syndrome combined with {epidemiology OR life expectancy OR systematic review OR leukemia OR CNS tumor OR brain tumors}. We typically reviewed the most recent reports and focused on large studies with adequate methodology. Because empirical data on the role of imaging in the diagnosis and monitoring of CSS patients were extremely sparse, we relied on expert opinion to inform scenarios concerning use of CTs among CSS patients for those CSS with the highest potential of confounding within the relevant timeframe from 1990 to 2012.
Quantitative assessment of confounding bias
Most previous and ongoing epidemiologic studies include patients who received at least one pediatric CT scan. We assume that all study participants receive some exposure and thus evaluate potential confounding for higher exposure compared to lower exposure. We estimate bias of the RR of leukemia or brain tumors by CT-related radiation exposure due to unmeasured confounding by a particular CSS as
where RR OBS is the RR of cancer comparing arbitrarily defined high and low exposure groups without adjustment for CSS, RR ADJ is the corresponding RR adjusted for the CSS, RR CD is the RR of cancer among CSS patients compared with others in the reference population, p HI is the CSS prevalence in the high exposed group, p LO is the CSS prevalence in the low exposed group, p 0 is the CSS prevalence in the general population. Let g=p HI /p LO and f =p LO /p 0 , so that the CSS prevalence in the high exposed group is a multiple of the prevalence in the low exposed (reference) group, p HI =g*p LO, while the prevalence in the low exposed group is a multiple of that in the general population, p LO =f*p 0 , where p 0 is the prevalence in the general population (19 We use values of 1,…,5 for f and 1,….,8 for g. For example, one scenario assumes that the prevalence of a particular CSS among low exposed subjects is twice the general population prevalence (f=2), while the CSS prevalence among high exposed subjects is 5-fold that among the low exposed (g=5), i.e., 10-fold the general population prevalence (p HI =2*5*p 0 ). Since p 0 is small, this is equivalent to CSS patients being 2-and 10-fold more likely to be in the low and high exposed group, respectively, compared with subjects without the CSS.
We also calculated collective bias from all CSS predisposing to leukemia (and/or brain tumors) by summing their prevalences and calculating the corresponding cancer risk as the mean of CSS-specific risks weighted by CSS prevalence. Finally, we considered life expectancy of all CSS. If life expectancy was severely limited, confounding would also be limited since the contribution of person-years from CSS patients would be very small and cancer events would not contribute to the high exposed categories due to commonly used lagging of exposure metrics by several years in this type of research.
Results

Identification and characterization of cancer susceptibility syndromes
We identified 31 CSS ( 
Confounding of leukemia risk due to specific CSS
DS is a genetic disorder caused by the presence of all or part of a third copy of chromosome 21, and has a prevalence of about 160/100,000 (20) . It is typically associated with physical growth delays, characteristic facial features, and mild to moderate intellectual disability.
Leukemia risk among patients with DS is about 50-fold the rate in the general population (21) .
Ignoring confounding from DS could maximally bias leukemia RRs about 2.0-fold (p HI =8p LO , p LO /p 0 =5, Figure 1a) .
Results for DS indicate that the potential for confounding depends on the excess frequency of CT scans among DS patients. Based on a recent review (22) , imaging modalities other than CT were adequate for DS patients in most clinical situations (Supplementary Table S1 ). For Noonan syndrome and leukemia, the unadjusted RR overestimated the adjusted RR by maximally 30% (Figure 1b ). Other CSS were either less prevalent or their association with leukemia was weaker, or both, resulting in bias of 10% or less.
Confounding of brain tumor risk due to specific CSS
TSC is an autosomal-dominant neurocutaneous disorder with a prevalence of about 8/100,000 (26). It is characterized by tumors involving many organ systems including the brain, heart, kidneys and skin, as well as other organ dysfunction and mental retardation. Subependymal giant cell tumors (SEGAs), which develop in 9-14% of patients and almost always occur before 20-25 years of age (27) , are a major feature specific for TSC (15) . Bias can be up to 4-fold ( Figure 2a ). In the past, screening for SEGAs was recommended among children with TSC using CT or magnetic resonance imaging (MRI) of the head every 1-3 years (28). MRI appears to be the preferred modality in more recent years (29) Other CSS were either less prevalent or their association with brain tumors was weaker, or both. As a consequence, bias was 10% or less.
Confounding bias due to combined CSS
Combining all CSS predisposing to leukemia resulted in a potential confounder with a prevalence of 282/100,000 and a RR for leukemia of 14.8. This combination of prevalence and RR resulted in no additional confounding besides that from DS/VHL (data not shown).Any CSS predisposing to brain tumors were prevalent at 113/100,000 and carried a 713-fold elevated brain tumor risk, which resulted in confounding of the same magnitude as VHL alone (data not shown). 
Discussion
Our evaluation suggests that leukemia-predisposing CSS do not substantially confound the association between radiation exposure from pediatric CT scans and leukemia risk because they are too rare and/or too weakly associated with leukemia or, in the case of DS, CT uptake is only moderately elevated among patients, if at all.
Brain tumor risks might be substantially confounded by TSC, while other brain tumorpredisposing CSS are unlikely to cause meaningful confounding. Since these conclusions are based on assumptions about CT use among CSS patients, robust empirical data are urgently needed.
Confounding by TSC can be controlled through adjustment for TSC or exclusion of subjects with TSC. The most promising source of such data for linkage with epidemiologic cohorts might be lists of TSC patients from hospitals treating TSC patients, which are usually limited to a few highly specialized medical centers. In contrast, hospital discharge registries or registries of congenital disorders might not be complete for TSC since hospitalization is often not required and most diagnoses do not occur perinatally (35) Exclusion of subjects who developed SEGAs will remove confounding; however, limiting follow-up to post-1999 will substantially compromise the statistical power of our study. 
A relevant question is whether bias due to CSS can create a dose-response relationship in the absence of a causal association between radiation and cancer. We did not directly evaluate bias of the linear excess relative risk per Gray (ERR/Gy), the commonly used measure of the strength of a dose-response between radiation exposure and cancer, because we are not aware of a published formula for the relative bias due to confounding. However, our results show that bias due to CSS can create increasing RR estimates for categories of increasing radiation exposure in the absence of a causal association, but only in very specific circumstances. If CT scanning among patients with a particular CSS is such that the prevalence of CSS patients increases across categories of increasing dose, bias of RRs comparing subjects exposed at different levels with the same reference level will then also increase with exposure level, leading to a positive ERR/Gy. This does not require the cancer risk due to CSS to increase with radiation exposure.
Two studies with some information on indication for CT scanning have recently been published. The first study included 67,274 children who received at least one CT scan before age 10 years between 2000 and 2010 in one of 21 French hospitals and who were followed for, on average, 4.4 years, with cancer diagnosed before age 15 years was defined as the outcome of interest (5). ERRs for leukemia or brain tumors were not or only mildly attenuated after adjustment for Down or NF, respectively, based on hospital discharge information. More substantial attenuation of the brain tumor ERR was observed for the group of so-called 'other phakomatoses', which includes TSC. A note of caution in interpreting these findings is warranted, though. First, because of the small sample size and short follow-up, all confidence intervals were wide and included unity, and attenuation for any of the evaluated (groups of) CSS was less than about 10% of the confidence interval width. Second, ERRs were not on April 15, 2017. © 2015 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from attenuated when patients with relevant CSS were excluded from analysis (36) (37) (38) . Third, very high prevalences were observed for several CSS, most likely owing to over-representation of referral centers among participating hospitals, which limits the generalizability of these results for nation-wide samples. The second study followed 44,584 children who received at least one CT scan before age 15 years in the period 1980-2010 in one of 20 German hospitals for, on average, 3.6 years and ascertained cancers diagnosed before age 15 years (4). Standardized incidence ratios were non-significantly elevated for leukemia and brain tumors. Radiology reports, which were available for most of the 12 leukemias and 7 brain tumors, respectively, indicated potential confounding by indication for one brain tumor case. Exclusion of that case slightly attenuated the brain tumor SIR.
Our study has a number of limitations. Although patients with CSS suffer from a diverse spectrum of health complaints (15) for which CT scans are an appropriate diagnostic imaging modality (16) , actual quantitative health care utilization data are scarce and therefore we had to rely on subjective scenarios. For illustration, with 5-7% of all children in the Netherlands receiving at least one CT before their 18 th birthday, a 10-fold higher proportion among patients with a particular CSS implies that about 50-70% of CSS patients receive at least one CT. Second, for some of the CSS evaluated here, there is evidence of increased radiosensitivity (e.g., AT, XP, LFS) (15) . For those CSS, we might have underestimated bias since the CSS-related cancer risk increases with the level of radiation exposure. However, these CSS are very rare. Also, affected families and medical professionals are well aware of the radiosensitivity, which likely implies a prevalence of CT use lower than that of the general population. Therefore, these syndromes are very unlikely to be potent confounders. Third, expert opinions on the use of CT scans among patients with CSS reflect clinical practice in the Netherlands. We believe this does not limit the generalizability since results are likely similar both across Western countries with comparable number of pediatric CTs and for countries with higher levels of pediatric CT scanning, as long as CT scanning is more common across all indications. However, it should be noted that our results are only generalizable to countries with a roughly similar prevalence of a CSS. Fourth, confounding by other risk factors such as socio-economic status (SES), birth weight and parental smoking is beyond the scope of these analyses (39, 40) . Finally, although we thoroughly reviewed the literature, we were not able to find prevalence estimates for some CSS and those we found for others are very heterogeneous with regard to precision. Nevertheless, we believe that the CSS we identified cover all relevant situations, as evidenced by the fact that all fields in the lower right part of Table 2 are populated.
Besides CSS, other predisposing conditions can confound CT-related cancer risk, for instance, leukemogenic drugs or total body irradiation prior to stem cell transplantation for nonmalignant diseases, such as Fanconi anemia, aplastic anemia, immune system deficiencies, or congenital malformations in the nervous and circulatory system (41) . Confounding by these conditions, although not the objective of this report, can be easily assessed by assigning the condition to one of the cells in Table 2 . For example, Common Variable Immune Deficiency (CVID) has a prevalence of approximately one in 30,000 live births (42) and an increased risk of leukemia (43) although the magnitude is not known. Based on our results, even if leukemia risk was substantially increased, confounding bias would be negligible given the low prevalence.
In conclusion, our assessment of confounding of CT-related cancer risks indicates that associations with leukemia reported in previous studies (1) (2) (3) (4) (5) LO , and p 0 are the prevalences of Down syndrome in the high exposed, low exposed and general population, respectively (19) .
Example: Under the assumption that the prevalence of Down syndrome among low exposed subjects is 5 times the general population prevalence (p LO /p 0 =5), and among the high exposed subjects is twice that in the low exposed group (p HI =2*p LO =2*5p 0 , i.e., 10 times the general population prevalence), the RR of leukemia not adjusted for Down syndrome overestimates the RR adjusted for Down syndrome by 13%. is the RR of brain tumors comparing arbitrarily defined high and low (reference) exposure groups without adjustment for tuberous sclerosis complex, RR ADJ is the corresponding RR adjusted for tuberous sclerosis complex, RR CD is the RR of brain tumors due to tuberous sclerosis complex in the reference population, and p HI , p LO , and p 0 are the prevalences of tuberous sclerosis complex in the high exposed, low exposed and general population, respectively (19 
